Back to first-pass browser

First-pass extracted concept

tumor-infiltrating lymphocyte therapy

Candidate: concept label2 source documents2 linked claims
Jump to explainersJump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Aliases

TIL, TILs, TIL therapy, tumor-infiltrating lymphocytes

Extracted Explainers

What the tool is doing

Tumor-infiltrating lymphocyte therapy is listed as one of the current ACT modalities examined for ovarian cancer.

Source 1DOIPubMed

Tumor-infiltrating lymphocyte therapy is represented in the supplied summary as a key adoptive T-cell transfer approach discussed by the review.

Source 2DOIPubMed

What problem it solves

It uses tumor-reactive T cells as a cancer immunotherapy strategy.

Source 2DOIPubMed

What it does not solve

The available payload does not state the review's specific caveats about scalability, patient selection, or durability.

Source 2DOIPubMed

Alternatives

The review also covers CAR-T, checkpoint blockade, and neoantigen vaccine approaches.

Source 2DOIPubMed

Evidence Snippets

This review provides a comprehensive analysis of current ACT modalities, including tumor-infiltrating lymphocytes.
Evidence 1Source 1DOIPubMedprovenance
The supplied source summary explicitly identifies adoptive T-cell transfer studies emphasizing mutation-reactive TILs as central to the review's adoptive cell therapy section.
Evidence 2Source 2DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1modality taxonomysupports2026Source 1DOIPubMed

Current ACT modalities discussed for ovarian cancer include tumor-infiltrating lymphocytes, T cell receptor-engineered therapies, and chimeric antigen receptor-T cell therapies.

Quoted textsource-backed
This review provides a comprehensive analysis of current ACT modalities, including tumor-infiltrating lymphocytes, T cell receptor-engineered, and chimeric antigen receptor-T cell therapies.
Claim 2review scopesupports2020Source 2DOIPubMed

This review synthesizes cancer immunotherapy from T-cell basic science through clinical practice, including checkpoint blockade, adoptive cellular therapy, CAR-T, and neoantigen-directed approaches.